Acadia Healthcare Company, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Acadia Healthcare Company, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	2,811	2,836	1,905	2,008	2,090	2,314	2,610	2,929	3,154	3,313
General and administrative	86.8	76.4	86.6	90.4	97.8	108	124	153	157	178
Operating expenses	2,778	2,600	3,181	2,971
Operating income	609	604	594	586
Pre-tax income	33	237	67.4	78.4	184	276	374	-25.4	342	-1,066
Income tax	28.8	37.2	9.91	25.1	40.6	67.6	94.1	-9.7	77.4	26
Income from continuing operations	6.14	200	57.2	52.1	140	203	273	-21.7
Net income to minority interests	-1.97	-0.25	0.26	1.2	2.93	4.93	6.89	6.01	8.87	10.8
Net income	6.14	200	-176	109	-672	191	273	-21.7	256	-1,103
EBITDA	744	747	674	674
EPS, basic	0.07	2.30	-2.01	1.24	-7.65	2.15	3.05	-0.24	2.79	-12.16
EPS, diluted	0.07	2.30	-2.01	1.24	-7.59	2.10	2.98	-0.24	2.78	-12.16
Shares, basic (weighted)	85.7	86.9	87.3	87.6	87.9	88.8	89.7	90.9	91.6	90.7
Shares, diluted (weighted)	86	87.1	87.4	87.8	88.6	90.8	91.6	90.9	92.1	90.7

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	57.1	67.3	50.5	99.5	379	134	97.6	100	76.3	133
Receivables	263	297	318	289	274	281	322	361	365	441
Inventory	4.63	4.79	5.06	4.08	4.85	4.79	5.09	5.3	5.65	5.69
Other current assets	108	107	81.8	65	61.3	79.9	86	134	136	240
Total current assets	428	472	450	542	2,523	495	506	596	577	814
Property, plant and equipment	2,704	3,048	3,108	1,500	1,623	1,771	1,952	2,267	2,853	3,111
Lease right-of-use assets				97.8	96.9	134	135	118	118	134
Goodwill	2,681	2,751	2,045	2,085	2,105	2,200	2,223	2,226	2,265	1,296
Intangible assets	83.3	87.3	89	68.8	68.5	70.1	76	73.3	70	96.7
Other non-current assets	51.3	49.6	64.9	55.1	79.1	95	92.7	72.6	52	72.6
Total assets	6,025	6,425	6,173	6,879	6,499	4,768	4,988	5,359	5,957	5,527
Accounts payable	80	102	118	90.3	87.8	98.6	105	156	233	150
Accrued liabilities	37.3	37.3	113	93.6	125	138	125	142	155	189
Deferred revenue	28.8	31.3	32.2	1.9	35.9	30.4	6.65	2.17	1.69	2.81
Short-term debt	34.8	34.8	34.1	43.7	153	18.6	21.3	29.2	76.8	28.4
Total current liabilities	343	377	416	464	1,308	405	388	886	578	525
Long-term debt	3,253	3,205	3,159	3,105	2,969	1,479	1,365	1,343	1,880	2,472
Lease liabilities				85.6	84	117	116	101	102	122
Other non-current liabilities	165	166	154	107	133	111	125	140	122	202
Total liabilities	3,839	3,829	3,810	4,341	4,545	2,185	2,087	2,471	2,766	3,387
Total debt	3,288	3,240	3,193	3,149	3,122	1,497	1,386	1,372	1,957	2,500
Paid-in capital	2,496	2,518	2,542	2,558	2,580	2,636	2,658	2,649	2,685	2,714
Retained earnings	220	429	253	362	-310	-120	153	132	387	-766
Other comprehensive income	-550	-374	-462	-415	-371
Shareholders' equity	2,168	2,573	2,333	2,505	1,899	2,517	2,813	2,782	3,074	1,949
Minority interests	17.8	22.4
Total equity	2,185	2,595	2,333	2,505	1,899	2,517	2,813	2,782	3,074	1,949
Total liabilities and equity	6,025	6,425	6,173	6,879	6,499	4,768	4,988	5,359	5,957	5,527
Shares outstanding	86.7	87.1	87.4	87.7	88	89	89.9	91.3	91.8	90.5

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	4.18	200	-175	110	-669	196	280	-15.7	264	-1,092
Depreciation and amortization	135	143	80.3	87.9	95.3	107	118	132	150	189
Stock-based compensation	28.3	23.5	22	17.3	22.5	37.5	29.6	32.3	37.1	31.7
Deferred income tax	28.6	31.4	-6.74	1.09	53.1	11.8	16.5	-94	67.7	1.09
Change in receivables	-15.7	-28.6	-19.7	-18.7	15.3	2.45	-42	-39	-2.33	-75
Change in payables	22.7	-10.1	7.7	-20.1	41.9	6.16	5.17	17.4	-421	14.9
Cash from operations	361	400	414	333	659	374	381	462	130	132
Capital expenditures	-307	-274	-253	-233	-225	-245	-296	-424	-690	-572
Acquisitions	-683	-18.2		-44.9		-139	-9.51	-0.35	-53.6	-8.17
Cash from investing	-660	-337	-361	-201	-282	1,013	-306	-397	-736	-556
Debt issued	1,480				925	425			350	1,200
Debt repaid	-201	-22.5	-21.9		-910	-2,228				-671
Stock issued	217
Share buybacks										-50
Cash from financing	359	-60.1	-67.3	-61.6	-51.5	-1,637	-111	-62.7	583	481
Exchange rate effect	-14.1	7.25	-2.57
Net change in cash	45.8	10.2	-37.1	49	255	-245	-36.2	2.42	-23.8	56.9
Free cash flow	54	125	161	100	434	130	84.4	38.2	-561	-440
Interest paid	161	159	175	173	138	93.7	65.7	80.7	113	125
Income taxes paid	15.5	10.3	6.14	31.9	-16.5	79.3	86.2	66.4	28.1	30.1

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to March 31, 2026; growth uses fiscal years. Valuation uses the share price of $28.09 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Pre-tax margin	-31.7%	Pre-tax income / revenue.
Net margin	-32.8%	Net income / revenue.
FCF margin	-8.7%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	5.4%	Cash from operations / revenue.
Return on equity (ROE)	-56.5%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-20.0%	Net income / average total assets.
Stock-based pay / revenue	0.9%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	14.1%	Capital expenditures / revenue.
D&A / revenue	5.8%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	5.0%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	8.3%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	9.7%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	-531.4%	Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y	-537.4%	EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y	1.7%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	-29.8%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	-27.5%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	-36.6%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-11.5%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	0.5%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-7.2%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	3.5%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-3.2%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-1.5%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-0.3%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	0.5%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	1.71x	Current assets / current liabilities.
Quick ratio	1.29x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.32x	(Cash + short-term investments) / current liabilities.
Debt / equity	1.29x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	45.6%	Total debt / total assets.
Liabilities / assets	60.9%	Total liabilities / total assets.
Net debt	$2.37B	Total debt - cash - short-term investments. Negative means more cash than debt.
Working capital	$347.8M	Current assets - current liabilities.
Goodwill and intangibles / assets	25.2%	(Goodwill + intangible assets) / total assets.
Tangible book value	$558.3M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.61x	Revenue / average total assets.
Fixed asset turnover	1.09x	Revenue / average property, plant and equipment.
Receivables turnover	7.15x	Revenue / average receivables.
Days sales outstanding	51 days	365 x average receivables / revenue.
Capex / operating cash flow	260.4%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$12.18	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$37.10	Revenue / diluted weighted shares.
FCF per share	-$3.21	Free cash flow / diluted weighted shares.
Operating cash flow per share	$2.00	Cash from operations / diluted weighted shares.
Book value per share	$21.58	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$6.15	Tangible book value / shares outstanding.
Cash per share	$1.75	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$2.62B	Share price x shares outstanding.
Enterprise value	$4.98B	Market cap + total debt - cash - short-term investments.
P/S	0.78x	Market cap / revenue.
P/B	1.34x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	4.68x	Market cap / tangible book value, when positive.
P/OCF	14.4x	Market cap / cash from operations, when positive.
EV/Sales	1.48x	Enterprise value / revenue.
FCF yield	-11.2%	Free cash flow / market cap.
Earnings yield	-42.3%	Net income / market cap (the inverse of P/E).

What was Acadia Healthcare Company, Inc.'s revenue in fiscal 2025?

Acadia Healthcare Company, Inc. reported revenue of $3.31B for fiscal 2025, 5% higher than the year before.

Was Acadia Healthcare Company, Inc. profitable in fiscal 2025?

No. It reported a net loss of $1.10B.

How much free cash flow did Acadia Healthcare Company, Inc. generate in fiscal 2025?

Cash from operations of $131.9M minus capital expenditures of $571.8M left free cash flow of -$439.9M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Acadia Healthcare Company, Inc.